Yahoo Web Search

Search results

1. • 

     Zai Lab doses first subject in Phase II plaque psoriasis treatment trial

     Clinical Trials Arena via Yahoo Finance· 2 days ago

     The randomised, global, double-blind, vehicle-controlled, dose-ranging trial is designed to assess...

2. • 

     Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief

     Verywell Health via Yahoo News· 4 days ago

     My arms were cherry red due to...in 2010, but knowing I wanted more babies deterred me from seeking ...

3. • 

     Home Phototherapy for Psoriasis: Optimizing Access

     Medscape· 3 days ago

     Supporters of home phototherapy for patients with plaque and guttate psoriasis had plenty to cheer about at the annual meeting of the American Academy of...

4. • 

     J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial

     Clinical Trials Arena via Yahoo Finance· 4 days ago

     J&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...

5. • Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

     Morningstar· 5 days ago

     “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey...

6. • UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...

     KTLA-TV Los Angeles· 2 days ago

     In these studies, bimekizumab consistently demonstrated sustained improvements in clinical...

7. • Swiss National Bank Cuts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

     ETF DAILY NEWS· 9 hours ago

     Swiss National Bank trimmed its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 9.8% in the 4th quarter, according to the company in its most recent Form ...

8. • Ultravate side effects: What they are and how to manage them

     Healthline· 5 days ago

     Ultravate (halobetasol propionate) is a prescription drug that’s used to treat plaque psoriasis. Ultravate can cause side effects that range from mild to ...

9. • TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...

     FOX 23 News Albany· 5 days ago

     ...20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative colitisa (UC) receiving subcutaneous (SC) TREMFYA® (guselkumab) 200 mg...

10. • AbbVie (NYSE:ABBV) vs. Cosmo Pharmaceuticals (OTC:CMOPF) Head to Head Review

      ETF DAILY NEWS· 11 hours ago

      AbbVie (NYSE:ABBV – Get Free Report) and Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses ...